Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 13/20 | 1.00 |
| ▸ | GSK3B | P49841 | 13/20 | 1.00 |
| ▸ | RGS4 | P49798 | 4/20 | 0.40 |
| ▸ | RGS8 | P57771 | 4/20 | 0.40 |
| ▸ | RGS16 | O15492 | 1/20 | 0.40 |
| ▸ | RGS19 | P49795 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382637 | 0.83 | GSK3A (1.00) | GSK3AGSK3BRGS4RGS8MGLL | |
| SCHEMBL3382636 | 0.81 | GSK3A (1.00) | GSK3AGSK3BRGS4RGS8MEN1 | |
| SCHEMBL3384007 | 0.81 | GSK3B (1.00) | GSK3AGSK3BGAACCNB2CDK1 | |
| SCHEMBL3384147 | 0.79 | GSK3A (1.00) | GSK3AGSK3BRGS4RGS8MGLL | |
| SCHEMBL17537368 | 0.73 | GSK3A (0.55) | GSK3AGSK3BMGLLMEN1POLB | |
| SCHEMBL23643021 | 0.71 | GSK3A (0.60) | GSK3AGSK3BRGS4RGS8RGS16 | |
| SCHEMBL6427982 | 0.66 | GSK3A (0.69) | GSK3AGSK3BMGLLCCNB2CDK1 | |
| SCHEMBL12660985 | 0.65 | MGLL (0.48) | GSK3AGSK3BMGLLPOLB | |
| SCHEMBL23643016 | 0.64 | GSK3A (0.47) | GSK3AGSK3BMGLLMEN1POLB | |
| SCHEMBL9710845 | 0.64 | GSK3A (0.46) | GSK3AGSK3BMGLLMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781463-B2 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | disclosed |
| US-7666885-B2 | Neurodegenerative disease; anticancer agents; hyperplasia; arterosclerosis; restenosis; non-insulin dependent diabetis; Alzheimer's disease | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-02-23 | — | — | US | disclosed |
| US-20080033012-A1 | Enzyme inhibitors | COSENJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2008-02-07 | — | — | US | disclosed |
| US-6872737-B2 | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2005-03-29 | — | — | US | disclosed |
| US-20050014803-A1 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033012-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3A 2/4885GSK3B 1/4885RGS4 4674/4885 |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885RGS4 3476/4885 |
| US-20050014803-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3A 2/4885GSK3B 1/4885RGS4 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.